tbuckley/cabot-search huggingface dataset:
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation
Authors: Samer A. Srour, Rima M. Saliba, Maria C. B. Bittencourt, Jorge M. R. Perez, Piyanuch Kongtim, Amin Alousi, Gheath Al‐Atrash, Amanda Olson, Oran Betul, Rohtesh Mehta, Uday Popat, Chitra Hosing, Qaiser Bashir, Issa Khouri, Partow Kebriaei, Lucia Masarova, Nicholas Short, Elias Jabbour, Naval Daver, Marina Konopleva, Farhad Ravandi, Hagop Kantarjian, Richard E. Champlin, Stefan O. Ciurea
Journal: American Journal of Hematology (2019)

Abstract There have been conflicting results regarding the impact of minimal/measurable disease at transplant on acute myeloid leukemia (AML) outcomes after haploidentical transplantation (haplo‐SCT). We assessed the impact of pre‐transplant disease status on post‐transplant outcomes of 143 patients treated with haplo‐SCT using fludarabine‐melphalan (FM) conditioning and post‐transplant cyclophosphamide (PTCy). With a median follow‐up of 29 months, the two‐year PFS for all patients was 41%. Compared to patients in complete remission (CR) at transplant, those with active disease (n = 29) and CR with incomplete count recovery (CRi) (n = 39) had worse PFS. They had hazard ratios (HR) of 3.5 (95% CI: 2.05‐6.1; P &lt; .001) and 2.3 (95% CI: 1.3‐3.9; P = .002), respectively. Among patients who were in CR at transplant, there were no differences in PFS between those who had minimal residual disease (MRD) positive (n = 24), and MRD negative (n = 41) (HR 1.85, 95%CI: 0.9‐4.0; P = .1). In multivariable analysis for patients in CR, only age was predictive for outcomes, while MRD status at transplant did not influence the treatment outcomes. Our findings suggest that haplo‐SCT with FM conditioning regimen and PTCy‐based GVHD prophylaxis has a protective effect, and may potentially abrogate the inferior outcomes of MRD positivity for patients with AML. Patients with positive MRD may benefit from proceeding urgently to a haplo‐SCT, as this does not appear to negatively impact transplant outcomes.
Impact of TET2 Deficiency on Iron Metabolism in Erythroblasts: A Potential Link to Ring Sideroblast Formation
Authors: Kyoko Inokura, Tohru Fujiwara, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Kazuya Shimoda, Hideo Harigae
Journal: Blood (2014)
Mine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs
Authors: Andrea Ghelli Luserna di Rorà, Ilaria Iacobucci, Neil Beeharry, Maria Vittoria Falzacappa, Chiara Ronchini, Cristina Papayannidis, Enrica Imbrogno, Anna Ferrari, Valentina Robustelli, Antonella Padella, Giovanni Martinelli, Timothy Yen
Journal: Blood (2016)
Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)
Authors: Laura Moreno, Aintzane Zabaleta, Diego Alignani, Daniel Ajona, Marta Lasa, Patricia Maiso, Tomas Jelinek, Victor Segura, Jose Antonio Delgado, Paula Rodriguez-Otero, Felipe Prosper, Jesus San Miguel, Bruno Paiva
Journal: Blood (2016)
Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation.
Authors: Sofia Qureshi, Manish Sharma, Chitra Hosing, Floralyn L Mendoza, Jatin Shah, Amin Alousi, Paolo Anderlini, Partow Kebriaei, Issa F Khouri, Uday Popat, Marcos de Lima, Richard E Champlin, Sergio Giralt, Muzaffar H. Qazilbash
Journal: Blood (2009)
Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.
Authors: Guntram Buesche, Aristoteles Giagounidis, Gudrun Göhring, Brigitte Schlegelberger, Stephanie Dieck, Robert Knight, Carlo Aul, Hans H. Kreipe
Journal: Blood (2012)
Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM)
Authors: David S. Siegel, Jonathan L. Kaufman, Noopur S. Raje, Joseph R. Mikhael, Prashant Kapoor, Steven P. Treon, Jorge J. Castillo, Linda L. Neuman, Ju RueyJiuan Lee, Irene Ghobrial
Journal: Blood (2014)
Efficacy of Dose-Dense R-CHOP-14 Chemoimmunotherapy Plus Pegfilgrastim for First-Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) in Low Risk Patients: An Interim Analysis of an Open-Label Clinical Trial in Spain. On Behalf of GEL/TAMO (Spanish Group of Lymphoma).
Authors: Eva Gonzalez-Barca, Antonio Salar, Joan Bargay, Jose F. Tomas, Miguel A. Canales, Jose M. Moraleda, Maria Jesus Vidal, Secundino Ferrer, Javier Briones, Cristina Estany, Santiago Gardella, Andres Llorente, Dolores Caballero
Journal: Blood (2007)
Pharmacodynamic Monitoring of the Efficacy of a Targeted Therapy with Midostaurin By Plasma Inhibitor Activity (PIA) Analysis in FLT3 -ITD Positive AML Patients within the AMLSG 16-10 Trial: A Study of the AML Study Group (AMLSG)
Authors: Frauke Theis, Peter Paschka, Daniela Weber, Verena I. Gaidzik, Lars Bullinger, Maria-Veronica Teleanu, Gudrun Göhring, Helmut R. Salih, Andrea Kündgen, Hans-Juergen Salwender, Joerg Westermann, Walter Fiedler, Katharina Götze, Heinz-August Horst, Gerald G Wulf, Michael Luebbert, Dominik Wolf, Thomas Kindler, Mark Ringhoffer, Doris Kraemer, Jürgen Krauter, Felicitas Thol, Michael Heuser, Arnold Ganser, Hartmut Döhner, Richard F. Schlenk, Konstanze Döhner
Journal: Blood (2015)
Association Between TNF and TNF Receptor II Gene Polymorphisms and Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Haematopoietic Stem Cell Transplantation within Chinese Population.
Authors: Haowen Xiao, Xiaoyu Lai, Gongqiang Wu, Yi Luo, Jimin Shi, Yamin Tan, Xiaoyan Han, Xiaoli Zhu, Jingjing Zhu, Wanzhuo Xie, Jingsong He, Zhen Cai, Maofang Lin, Xiujin Ye, He Huang
Journal: Blood (2009)
New red meat guidelines are undermined by undisclosed ties and faulty methods, say critics
Authors: Owen Dyer
Journal: BMJ (2019)

New guidelines on red and processed meat1 that cast doubt on the health benefits of reducing consumption have come under fire from critics who note that the lead author of the principal paper also helped to write a 2016 paper questioning the benefits of limiting sugar intake,2 which was funded by an industry group.

Bradley Johnston, an epidemiologist at Dalhousie University in Canada, did not disclose this previous funding in the conflict of interest declaration for the new red meat guidelines, which contradict most current expert advice in not recommending reduced consumption. The meat and sugar guidelines were both published in the Annals of Internal Medicine .

Johnston told The BMJ that, although the sugar research paper was published in late 2016, the funding was received in 2015, and hence he did not refer to it in the journal’s conflict of interest questionnaire for the new guidelines, which asked about financial conflicts from …
Antimir-21 Causes Autophagy in the K562 Cell Line and Sensitizes Cells to the Effect of Doxorubicin and Etoposide
Authors: Hugo Seca, Raquel T. Lima, Vanessa Lopes-Rodrigues, Jose E. Guimaraes, Gabriela M. Almeida, M. Helena Vasconcelos
Journal: Blood (2012)
Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
Authors: Matt Christopher, Allegra A. Petti, Christopher Miller, Lukas D. Wartman, Jacqueline E. Payton, Sharon Heath, Robert Fulton, John S. Welch, Matthew J. Walter, Peter Westervelt, Daniel C. Link, Richard K Wilson, Timothy J. Ley, John F. DiPersio
Journal: Blood (2016)
The Novel Histone Deacetylase Inhibitor RAS2410 (Resminostat) Interferes with Important Signalling Pathways and Induces Apoptosis in Multiple Myeloma Cells.
Authors: Philipp Baumann, Sonja Mandl-Weber, Felix Meinel, Ruediger Jankowsky, Fuat S. Oduncu, Ralf Schmidmaier
Journal: Blood (2009)
Somatic Mutations of the Breast Cancer Amplified Sequence-1 (BCAS1), a Novel Leukemogenic Driver in Myelodysplastic Syndromes with Del(20q)
Authors: Valeria Visconte, Ali Tabarroki, John Barnard, Li Zhang, Juraj Bodo, Reda Mahfouz, Betty K. Hamilton, Mikkael Sekeres, Anjali S. Advani, Matt E. Kalaycio, Yogen Saunthararajah, Velizar Shivarov, Shashirekha Shetty, Heesun J. Rogers, Ramon V. Tiu
Journal: Blood (2014)
IgD Myeloma: Clinical Features and Outcome In The Era Of Novel Agents
Authors: Flora Zagouri, Efstathios Kastritis, Argiris S. Symeonidis, Nikolaos Giannakoulas, Eirini Katodritou, Sosana Delimpasi, Panagiotis Repousis, Stavroula Giannouli, Eudokia M. Mandala, Evangelos Terpos, Meletios A. Dimopoulos
Journal: Blood (2013)
Tumor immunotherapy targeting <i>WT1</i> (Wilms’ tumor gene) peptide for bone and soft-tissue sarcomas: A preliminary report
Authors: T. Ueda, S. Kakunaga, Y. Oka, Y. Oji, A. Tsuboi, N. Hashimoto, A. Myoui, K. Aozasa, H. Sugiyama, H. Yoshikawa
Journal: Journal of Clinical Oncology (2007)

10042 Background: WT1 (Wilms’ tumor gene) is originally isolated as a tumor-suppressor gene in a subset of Wilms’ tumors, however, recent studies have indicated its oncogenic activity in various types of cancers, and demonstrated that WT1-specific cytotoxic T lymphocytes specifically kill WT1-expressing cancer cells, thus WT1 protein can be a molecular target for cancer immunotherapy as an attractive tumor rejection antigen. However, WT1 expression in human bone and soft-tissue sarcomas has been poorly understood. Methods: 1) The expression levels of WT1 gene were examined in 36 cases of various types of human bone and soft-tissue sarcomas using quantitative RT-PCR method. They included 12 MFH (11 soft-tissue, 1 bone), 9 osteosarcomas, 6 synovial sarcomas, 4 myxoid liposarcomas, 3 MPNST, one each case of angiosarcoma and clear cell sarcoma. 2) Then, we conducted a phase I/II clinical trial of tumor-specific immunotherapy targeting WT1 peptide for various kinds of cancers including 12 patients with locally advanced and/or metastatic sarcoma (bone 2, soft-tissue 10) which showed WT1 expression and HLA -A*2402. Patients were intracutaneously injected with 3.0mg of HLA- A*2402-restricted natural/or modified 9-mer WT1 peptide emulsified with Montanide ISA51 adjuvant weekly. After 12-times injection, clinical response was evaluated by RECIST. Results: 1) 28 (78%) out of 36 cases of various types of bone and soft-tissue sarcomas overexpressed the WT1 gene, and its expression at the protein level was confirmed by immunohistochemical analysis, suggesting a possibility of immunotherapy using WT1 peptide vaccine for sarcomas. 2) The clinical responses included 4 SD and 7 PD with a case of long-standing SD over 1.5 years. One patient discontinued treatment with patient's decision. There were no patients with objective response (PR/CR). Conclusion: The present preliminary study suggested that tumor immunotherapy using WT1 peptide vaccine can be a new treatment strategy for patients with bone and soft-tissue sarcomas. No significant financial relationships to disclose.
Incidence and Risk Factors for Thromboembolism in Patients with Hematologic Malignancies Undergoing Allogeneic and Autologous Stem Cell Transplantation.
Authors: Nicole M. Kuderer, Alok A. Khorana, Jonathan W. Friedberg, Eva Culakova, Gordon L. Phillips, Charles W. Francis, Gary H. Lyman
Journal: Blood (2004)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Secondary Pulmonary Alveolar Proteinosis with Trisomy-8 Myelodysplastic Syndrome
Authors: Aya Nishida, Hikari Ota, Taichi Ikebe, Kazuya Ishiwata, Masanori Tsuji, Hisashi Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Koji Izutsu, Atsushi Wake, Akiko Yoneyama, Shigeyoshi Makino, Shuichi Taniguchi
Journal: Blood (2011)
Panobinostat Induces Upregulation of CD38 and Augments the Anti-Myeloma Efficacy of Daratumumab in Pre-Clinical Models
Authors: Estefania Garcia-Guerrero, Tea Gogishvili, Sophia Danhof, Martin Schreder, Celine Pallaud, Thomas Lehmann, Hermann Einsele, Michael Hudecek
Journal: Blood (2016)
ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-Cell Receptors (ACTR), Induces Complete Responses in Patients with Relapsed or Refractory CD20-Positive B-Cell Lymphoma, in Combination with Rituximab
Authors: Luke Paul Akard, Samantha Jaglowski, Steven M. Devine, Matthew S. McKinney, Michael Vasconcelles, Heather Huet, Seth Ettenberg, Ann Ranger, Jeremy S. Abramson
Journal: Blood (2017)
An Interim Evaluation of Systemic F-Ara-a Exposure in Pediatric Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients Using An Optimal Sampling Design
Authors: Janel R Long-Boyle, Shirley Yan, Christopher C. Dvorak, Biljana N. Horn, Morton Jerome Cowan, Liusheng Huang, Nancy Sambol, Lisa Musick, Francesca Aweeka
Journal: Blood (2011)
Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL)
Authors: Elias Jabbour, Kantarjian Hagop, Deborah Thomas, Guillermo Garcia-Manero, Daniela Hoehn, Rebecca Garris, Stefan H. Faderl, Jorge E. Cortes, Tapan M. Kadia, Farhad Ravandi, Srdan Verstovsek, Susan O'Brien
Journal: Blood (2013)
A Comparison of Stem Cell Source in Adult and Paediatric Recipients of T-Cell Depleted Myeloablative Transplants for Standard Risk Leukaemia: No Difference in Mortality Using BM or PBSC.
Authors: Bronwen E Shaw, Jane Apperley, Nigel H. Russell, Charles F. Craddock, Effie Liakopoulou, Michael N Potter, Robert Wynn, Brenda ES Gibson, R. Pearce, Keiren Kirkland, Alejandro Madrigal, Gordon Cook, Jennifer L Byrne
Journal: Blood (2009)
An Ongoing, Observational Cohort Study in Multiple Myeloma (PREAMBLE): Preliminary Efficacy Analyses in Patients with 1 Line of Prior Therapy
Authors: Brian Durie, David J Kuter, Catherine Davis, Teresa Zyczynski, Hartmut Goldschmidt, Ravi Vij, Sergey Popov, David Cella, Gordon Cook
Journal: Blood (2016)
Characterization and Quantification Of Rare BCR-ABL1 Fusion Transcripts
Authors: Susanne Schnittger, Frank Dicker, Tamara Alpermann, Christiane Eder, Annette Fasan, Simone Weber, Sabine Jeromin, Manja Meggendorfer, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach
Journal: Blood (2013)
Idarucizumab, a Specific Antidote for Dabigatran, Cross-Reacts with Melagatran and May Also Interact with Other Benzamidine-Containing Compounds
Authors: Jawed Fareed, Larissa Reikensmeyer, Amanda Walborn, Debra Hoppensteadt, Jeanine M. Walenga, Eduardo Ramacciotti, Schuharazad Abro, Walter Jeske, Olivia Bouchard, Ismail Elalamy
Journal: Blood (2016)
Retrospective comparison between Nivolumab and Irinotecan for advanced gastric cancer
Authors: Takahiro Ishii, Akihito Kawazoe, Yoshiaki Nakamura, Akinori Sasaki, Saori Mishima, Daisuke Kotani, Yasutoshi Kuboki, Hiroya Taniguchi, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino, Takeshi Kuwata, Kohei Shitara
Journal: Annals of Oncology (2019)
Cellular Model of CEBPA N321D Captures Gene Expression Profile in the Transition to Pre-Leukaemic Status
Authors: Moosa Qureshi, Wajid Jawaid, Fernando J Calero-Nieto, Rebecca Hannah, Sarah J Kinston, Evangelia Diamanti, Winnie W Lau, Isabel Jimenez-Madrid, Chiara Cossetti, Berthold Gottgens
Journal: Blood (2016)
Sub-Morphologic Evidence of Disease Prior to Stem Cell Transplantation Correlates with Inferior Post Transplant Outcome in Childhood Acute Myeloid Leukemia.
Authors: Abby R. Rosenberg, Wendy Leisenring, Jean E Sanders, Ann E Woolfrey, Paul A. Carpenter, Denise A. Wells, Michael R. Loken, Soheil Meshinchi
Journal: Blood (2009)
Hypoplastic Myelodysplastic Syndrome (h-MDS) Is a Distinctive Clinical Entity with Poorer Prognosis and Frequent Karyotypic and FISH Abnormalities Compared to Aplastic Anemia (AA).
Authors: Youngil Koh, Hye Ryun Lee, Eun Young Song, Hyun Kyoung Kim, Inho Kim, Sung-Soo Yoon, Dong Soon Lee, Seonyang Park, Myoung Hee Park, Byoung Kook Kim
Journal: Blood (2009)
Clinical and Molecular Significance of Tumor Necrosis In Newly Diagnosed Patients with Hodgkin's Lymphoma and Diffuse Large B Cell Lymphoma
Authors: Ihab Abd-Elrahman, Vladimir Rapoport, Tzahi Neuman, Liat Appelbaum, Tamar Shiloach, Riki Perlman, Dina Ben-Yehuda
Journal: Blood (2010)
Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules
Authors: Andrew Clark, Jacqueline Tate, Umesh Parashar, Mark Jit, Mateusz Hasso-Agopsowicz, Nicholas Henschke, Benjamin Lopman, Kevin Van Zandvoort, Clint Pecenka, Paul Fine, Colin Sanderson
Journal: The Lancet Global Health (2019)

Infant rotavirus vaccines have led to substantial reductions in hospital admissions and deaths due to gastroenteritis, but some studies have reported an elevated risk of intussusception, a rare bowel disorder. This analysis aimed to provide evidence on the potential mortality reduction benefits and intussusception risks of current rotavirus vaccination schedules, and to explore whether alternative schedules could have advantages.All 135 low-income and middle-income countries, defined by gross national income per capita of less than US$12 236 in the 2018 fiscal year, were included in the model. Mortality reduction benefits and intussusception risks of rotavirus vaccination were modelled by use of an Excel-based static cohort model with a finely disaggregated age structure. Numbers of rotavirus gastroenteritis deaths and intussusception deaths in each week of age were calculated for all infants born in the year 2015 between birth and age 5·0 years, with and without restrictions on age at administration. Benefit-risk ratios (rotavirus gastroenteritis deaths prevented per excess intussusception death) and other indicators were calculated for two vaccination schedules currently recommended by WHO and 16 alternative schedules. Of these schedules, it was assumed that between one and three doses would be given; the first dose of the rotavirus vaccine would be co-administered with either BCG or diphtheria-tetanus-pertussis (DTP)1; and the second or third dose would be co-administered with either DTP1, DTP2, DTP3, or measles (Meas)1.A three-dose schedule co-administered with DTP (without age restrictions) could prevent about 74 000 (95% uncertainty interval 59 000-100 000) rotavirus gastroenteritis deaths (38% reduction) and could lead to 201 (77-550) excess intussusception deaths (1·4% increase) compared with no vaccination, resulting in a benefit-risk ratio of 369:1 (160:1-895:1). The benefit-risk ratio was most favourable when the relative risk of intussusception was assumed to decline with the national under-5 mortality rate (2386:1) and least favourable with pessimistic assumptions about access to hospital for intussusception treatment (168:1). Schedules that involve giving the first dose with BCG and the second with DTP1 had the fewest excess intussusception deaths and most favourable benefit-risk ratios.Rotavirus vaccines have a favourable benefit-risk profile in LMICs. Neonatal schedules have the potential to prevent more rotavirus gastroenteritis deaths and cause fewer excess intussusception deaths than the schedules currently recommended by WHO, but more efficacious rotavirus vaccines would be needed to achieve more substantial mortality reduction benefits.Bill & Melinda Gates Foundation.
Molecular and Prognostic Correlates of Cytogenetic Abnormalities in Chronic Myelomonocytic Leukemia: A Mayo Clinic-French Consortium Study
Authors: Emnet A Wassie, Raphael Itzykson, Terra L Lasho, Olivier Kosmider, Christy Finke, Curtis A. Hanson, Rhett Ketterling, Eric Solary, Ayalew Tefferi, Mrinal M. Patnaik
Journal: Blood (2014)
Long-Term Outcomes of Autologous Hematopoietic Cell Transplantation Using Melphalan and Total Body Irradiation Conditioning in Multiple Myeloma
Authors: Ali Baghian, Reinhold Munker, Yordanka Koleva, Gunita Matharoo, Patricia Andrews, Ato Wright, Nakhle S. Saba, Hana Safah
Journal: Blood (2016)
The Internal-Tandem-Duplication of Flt3 Mutation Generates Growth Inhibitory Signals in Mouse Hematopoietic Progenitor Cells by Down-Regulating Pbx1 Expression Via P21cdkn1a.
Authors: Seiji Fukuda, Mariko Abe, Tomohiro Hirade, Chie Onishi, Louis M. Pelus, Seiji Yamaguchi
Journal: Blood (2012)
Induction Treatment In Elderly Patients with Acute Myeloid Leukemia (AML): Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) In 492 AML Patients &gt;60 Years – Results From the SAL 60plus Trial
Authors: Christoph Röllig, Michael Kramer, Mathias Hanel, Regina Herbst, Norbert Schmitz, Heinrich Bodenstein, Karl-Heinz Pflüger, Thomas Wagner, Martin Wolf, Martin Bornhäuser, Christian Thiede, Markus Schaich, Uwe Platzbecker, Friedrich Stölzel, Malte von Bonin, Hannes Wandt, Gerhard Ehninger, Ulrich Schuler
Journal: Blood (2010)
Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial
Authors: Annika Scheffold, Billy Michael Chelliah Jebaraj, Eugen Tausch, Sebastian Boettcher, Matthias Ritgen, Donald Bunjes, Matthias Zeis, Michael Stadler, Lutz Uharek, Christof Scheid, Ute Hegenbart, Michael Hallek, Michael Kneba, Norbert Schmitz, Hartmut Doehner, Peter Dreger, Stephan Stilgenbauer
Journal: Blood (2014)
The Impact of Relative Dose Intensity on Response and Survival in a Series of 180 Newly Diagnosed Patients with Hodgkin’s Lymphoma.
Authors: Filippo Russo, Gino Svanera, Paola Della Cioppa, Gaetano Corazzelli, Ferdinando Frigeri, Gaetana Capobianco, Secondo LaStoria, Antonio Pinto
Journal: Blood (2005)
The LRF/ZBTB7A Transcription Factor Is a BCL11A-Independent Repressor of Fetal Hemoglobin
Authors: Takeshi Masuda, Xin Wang, Manami Maeda, Matthew C. Canver, Falak Sher, Alister P.W. Funnell, Chris Fisher, Maria Suciu, Gabriella E. Martyn, Laura J. Norton, Ruijia Zhu, Ryo Kurita, Yukio Nakamura, Jian Xu, Douglas R. Higgs, Merlin Crossley, Daniel E. Bauer, Stuart H. Orkin, Peter V. Kharchenko, Takahiro Maeda
Journal: Blood (2015)
Overlap of systemic lupus erythematosus and myositis is rare in anti-Ku antibody-positive patients
Authors: Mariko Ogawa-Momohara, Yoshinao Muro, Masashi Akiyama
Journal: Annals of the Rheumatic Diseases (2019)

Anti-Ku antibodies were originally reported as scleroderma-polymyositis (PM) overlap syndrome-related autoantibodies. However, they are also frequently found in various connective tissue diseases (CTDs) and their clinical significance has not been conclusively determined. Moreover, there are few studies on anti-Ku in Asian CTD cohorts. Recently, Spielmann et al 1 published a notable report of a French single-centre large-cohort study which tried to classify anti-Ku-positive patients with various CTDs and was able to identify two distinct subgroups of patients: ‘anti-Ku-positive patients with elevated serum creatine kinase (CK) levels’ and ‘anti-Ku-positive patients with anti-double-strand DNA antibodies (anti-dsDNA)’. Patients in the former group were at high risk of developing interstitial lung disease and those in the latter were at high risk of developing glomerulonephritis.

In the present study, we retrospectively screened sera from 600 Japanese patients with CTDs who visited our institute …
Prognostic Factors for Overall Survival in Relapsed Acute Myeloid Leukemia
Authors: Thomas Heinicke, Rainer Krahl, Christoph Kahl, Sebastian Scholl, Hans-Heinrich Wolf, Detlev Hähling, Ute Hegenbart, Norma Peter, Antje Schulze, Axel Florschütz, Kolja Reifenrath, Niklas Zojer, Christian Jakob, Christian Junghanss, Herbert G. Sayer, Georg Maschmeyer, Andreas Hochhaus, Thomas Fischer, Dietger Niederwieser, Haifa Kathrin Al-Ali
Journal: Blood (2014)
PAK1 Regulates Eotaxin-Mediated Murine Eosinophil Migration in Vitro and In Vivo
Authors: Muithi Mwanthi, Gracie Michels, Karl Staser, Sarita Sehra, Michal Jander, Shi Chen, David S Wilkes, Mark Kaplan, Su-jung Park, D. Wade Clapp
Journal: Blood (2011)
Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid Leukemia
Authors: Ryan G. Kruger, Helai Mohammad, Kimberly Smitheman, Monica Cusan, Yan Liu, Melissa Pappalardi, Kelly Federowicz, Glenn Van Aller, Jiri Kasparec, Xinrong Tian, Dominic Suarez, Meagan Rouse, Jessica Schneck, Jeffrey Carson, Patrick McDevitt, Thau Ho, Charles McHugh, William Miller, Neil Johnson, Scott A. Armstrong, Peter Tummino
Journal: Blood (2013)